Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat versus febuxostat + benzbromarone for primary gout with mixed-type hyperuricemia
ChiCTR2200055197Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of febuxostat and benzbromarone in gout and hyperuricemia (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Serum urate. Started Oct 2022; status: recruiting.
02
Drugs
febuxostatbenzbromarone
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on ChiCTR2200055197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055197.